A comprehensive update on the cost-effectiveness of 10-year denosumab vs alendronate in postmenopausal women with osteoporosis in the United States
Ten-year denosumab treatment would be cost-effective compared with 5 years of alendronate, followed by a 2-year drug holiday and 3 years of alendronate at the threshold of $150,000. Cost-effectiveness was demonstrated across most scenarios with robust PSA results.
Authors
- Eric J. Yeh (ORCID: https://orcid.org/0000-0002-9357-9626)
- Jack Badaracco (ORCID: https://orcid.org/0000-0003-3317-0965)
- Matia Saeedian
Institutions
- Amgen (United States) (US)
Publication Details
- Journal
- Archives of Osteoporosis
- Published
- 2025-06-30
- DOI
- https://doi.org/10.1007/s11657-025-01564-x
- Primary Topic
- Bone health and osteoporosis research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen